Skip to content

Exploratory study to evaluate the recurrence prediction factor in patients with completely resected colorectal cancer which has adjuvant therapy of XELOX.(KPUM-DS-C03)

Exploratory study to evaluate the recurrence prediction factor in patients with completely resected colorectal cancer which has adjuvant therapy of XELOX.(KPUM-DS-C03) - Exploratory study to evaluate the recurrence prediction factor in patients with completely resected colorectal cancer which has adjuvant therapy of XELOX.(KPUM-DS-C03)

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000011459
Enrollment
300
Registered
2013-08-12
Start date
2013-08-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

None listed

Sponsors

Kyoto Prefectural University of Medicine Department of Surgery Division of Digestive Surgery
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed colorectal cancer 2. High risk stage II or stage III 3. Curability A surgery 4. Age >= 20 years 5. ECOG performance status of 0-1 6. Treatment plan of XElOX adjuvant therapy 7. Adequate organ function 8. Signed written informed consent

Exclusion criteria

Exclusion criteria: 1. Prior oxaliplatin therapy 2. Prior chemotherapy or radiotherapy for colorectal cancer 3. Brain metastasis or active multiple malignancy 4. Peripheral nerve disorder 5. A history of severe drug allergy 6. Active infectious disease 7. Significant mental illness 8. Following complications i) Uncontrolled diabetes ii) Uncontrolled hypertension iii) Interstitial pneumonia iv) Iintestinal tract paralysis or ileus v) Significant heart trouble 9. Inadequate for study enrollment by the physician

Design outcomes

Primary

MeasureTime frame
Correlation of a clinical response and a clinicopathologic factor.

Secondary

MeasureTime frame
Correlation of Dose Intensity and Relapse Free Survival. Safety

Countries

Japan

Contacts

Public ContactMasayoshi Nakanishi

Kyoto Prefectural University of Medicine Division of Digestive Surgery

mnakan@koto.kpu-m.ac.jp075-251-5527

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026